INOVIO, a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, has appointed Steven Egge as Chief Commercial Officer.

Egge will lead the company’s commercial strategy and operations as it prepares to potentially launch its first DNA medicine product, INO-3107 as a treatment for recurrent respiratory papillomatosis (RRP).

“We are delighted to welcome Steve to INOVIO and look forward to adding his expertise to our leadership team as we continue advancing our preparations to commercially launch INO-3107 in 2025, should it receive approval by the FDA as a treatment for RRP,” said Dr. Jacqueline Shea, INOVIO’s President and CEO. “Steve joins us at an exciting time, as we prepare to become a commercial-stage company, while advancing multiple product candidates targeting unmet medical needs. His expertise launching new products, driving market share in competitive environments, and growing overall therapeutic areas will be advantageous to the development and implementation of our commercial plans, as will his experience across immunology and vaccines, HPV, and rare diseases.”

“This is a great time to join INOVIO as the company has the opportunity to market the first therapeutic option for patients suffering from RRP, a rare and debilitating HPV-related disease that significantly impacts quality of life,” said Egge. “I look forward to working with the talented team at INOVIO and continuing the ongoing efforts to build out the company’s commercial strategies and capabilities.”

Egge comes to INOVIO from Sumitomo Pharma (formerly Myovant Sciences, acquired by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma, in 2023), where as Senior Vice President and General Manager for Women’s Health he was responsible for building the commercial leadership team, accelerating the launch of Myfembree and helping lead the company’s expansion into new indications.

Egge was at Merck for twenty years, where he held a number of senior commercial leadership roles, including leading Merck’s HPV Vaccines Franchise as well as Chief Marketing Officer for the Vaccine Division, where he oversaw launches for new indications for GARDASIL, a re-launch of ZOSTAVAX, and launch planning for GARDASIL9 and VAXELIS. Egge also served as Global Commercial Head for Merck’s Fertility Franchise, where he oversaw the launch of ELONVA in ex-U.S. markets. After Merck, Egge served as Senior Vice President at Genfit Corp., a French biotech company focused on liver diseases, where he led commercial planning and business development.